Details for Patent: 8,921,357

Which drugs does patent 8,921,357 protect, and when does it expire?

Patent 8,921,357 protects TEPMETKO and is included in one NDA.

This patent has seventy-six patent family members in thirty-five countries.

Summary for Patent: 8,921,357

Title:	Pyridazinone derivatives
Abstract:	Compounds of the formula (I), in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.4' have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
Inventor(s):	Dorsch; Dieter (Ober-Ramstadt, DE), Stieber; Frank (Heidelberg, DE), Schadt; Oliver (Rodenbach, DE), Blaukat; Andree (Muehltal, DE)
Assignee:	Merck Patent GmbH (Darmstadt, DE)
Application Number:	13/785,471
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Process; Device;

Drugs Protected by US Patent 8,921,357

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emd Serono Inc	TEPMETKO	tepotinib hydrochloride	TABLET;ORAL	214096-001	Feb 3, 2021		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 8,921,357

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2007 032 507	Jul 12, 2007

International Family Members for US Patent 8,921,357

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	066543
Argentina	067505
Australia	2008274534
Australia	2008274670
Brazil	PI0813707